Premium
A subunit type of botulinum mucosal vaccine effectively induces protective immunity in non‐human primates
Author(s) -
Nochi Tomonori,
Yuki Yoshikazu,
Mejima Mio,
Ono Fumiko,
Katakai Yuko,
Shibata Hiroaki,
Kohda Tomoko,
Kozaki Shunji,
Terao Keiji,
Kiyono Hiroshi
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.853.4
Subject(s) - botulism , clostridium botulinum , antitoxin , botulinum neurotoxin , immunity , adjuvant , immune system , neurotoxin , botulinum toxin , microbiology and biotechnology , vaccination , virology , exotoxin , immunology , biology , medicine , toxin , anesthesia , biochemistry
Mucosally infected Clostridium Botulinum produces deadly poisonous exotoxin in the aero‐digestive tract and causes botulism. In spite of its high pathogenicity, effective vaccine against C. Botulinum has not been developed. We here prepared subunit antigen, C‐terminal half of heavy chain of botulinum neurotoxin (Hc), by E. coli expression system as a botulinum mucosal vaccine. Nasally immunized Hc induced high level of botulinum neurotoxin‐specific immune responses in both systemic and mucosal compartments of non‐human primates even in the absence of any mucosal adjuvant. Furthermore, immunized non‐human primates survived without any clinical sign after challenging with 25,000 LD50 dose of botulinum neurotoxin, while non‐immunized primates caused severe botulism within 3 hours. These results clearly show that mucosal vaccination with Hc is a novel strategy for the induction of protective immunity against botulism, which is naturally occurred or stemmed from acts of bioterrorism.